GL1X · GenesisL1 explorer

Research workbench

Drug resistant csrc kinase domain in complex with inhibitor RL45 (type II)

Analyse Drug resistant csrc kinase domain in complex with inhibitor RL45 (type II) in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
3F3W
Type
protein
Length
521 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Proto-oncogene tyrosine-protein kinase src
EC
2.7.10.2
UniProt
P00523
Ligands
1BU
Pockets
5 · best druggability 0.72

Structure

x-ray diffraction · 2 distinct chains · 42% helix, 17% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AProto-oncogene tyrosine-protein kinase src (EC 2.7.10.2)protein26141% helix, 17% strandP00523
BProto-oncogene tyrosine-protein kinase src (EC 2.7.10.2)protein26042% helix, 18% strandP00523

Ligands and binding sites

  • 1BU · 1-{4-[(6-aminoquinazolin-4-yl)amino]phenyl}-3-[3-tert-butyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]urea · ligand · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

5 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
17180.720.78631BU
24140.670.79411BU
33240.570.7631empty
41000.330.7320empty
5600.310.7515empty

Interfaces

1 interface between chains.

  • A–B · 355 Ų buried · 4 hydrogen bonds · protein-protein

Compared structures

  • 3F3W · Drug resistant cSrc kinase domain in complex with inhibitor RL45 (Type II) · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.